Advocacy through groups like BCAN and the AUA shapes urologic oncology policy—driving funding, screening access, and equity in cancer care, the authors write.
News|Articles|April 21, 2025
AUA 2025: What to watch for in urologic oncology
Fact checked by: Hannah Clarke
We preview several noteworthy P2 presentations in the urologic oncology space.
Advertisement
Advertisement
The American Urological Association (AUA) will try its luck in Las Vegas, Nevada for its 2025 annual meeting. Taking place at the Venetian Las Vegas from April 26-29 (and preceded by the AUA Innovation Nexus on April 25), the meeting will feature scientific abstracts, lectures, Crossfire Debates, the P2s: Practice-changing Paradigm-shifting Clinical Trials in Urology, and much more. In this article, we preview several noteworthy P2 presentations in the urologic oncology space. You can follow Urology Times’ coverage of the meeting
Related to this article
A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
The PDUFA target action date is in the fourth quarter of 2026.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
Better detection has changed prostate cancer care. Patients choosing radical treatment still need better protection from the disease returning.
Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and PCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.
Sandip Prasad, MD, MPhil, discusses the evolving role of chemoablation in recurrent low-grade, intermediate-risk NMIBC, including patient selection and treatment considerations.
Eugene Cone, MD, discusses recombinant BCG for NMIBC, including ongoing clinical evaluation and its potential to address ongoing BCG supply challenges.
Advertisement
Advertisement